Siramesine fumarate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529521

CAS#: 163630-79-3 (fumarate)

Description: Siramesine fumarate is a sigma receptor agonist potentially for the treatment of generalized anxiety disorder


Chemical Structure

img
Siramesine fumarate
CAS# 163630-79-3 (fumarate)

Theoretical Analysis

MedKoo Cat#: 529521
Name: Siramesine fumarate
CAS#: 163630-79-3 (fumarate)
Chemical Formula: C34H35FN2O5
Exact Mass: 0.00
Molecular Weight: 570.660
Elemental Analysis: C, 71.56; H, 6.18; F, 3.33; N, 4.91; O, 14.02

Price and Availability

Size Price Availability Quantity
10mg USD 275
25mg USD 565
Bulk inquiry

Related CAS #: 224177-60-0 (HCl)   147817-50-3 (free base)   163630-79-3 (fumarate)    

Synonym: LU-28-179; LU-28179; LU 28 179

IUPAC/Chemical Name: 1'-(4-(1-(4-fluorophenyl)-1H-indol-3-yl)butyl)-3H-spiro[isobenzofuran-1,4'-piperidine] fumarate

InChi Key: VONJQLKJOYOVBE-WLHGVMLRSA-N

InChi Code: InChI=1S/C30H31FN2O.C4H4O4/c31-25-12-14-26(15-13-25)33-21-23(27-9-2-4-11-29(27)33)7-5-6-18-32-19-16-30(17-20-32)28-10-3-1-8-24(28)22-34-30;5-3(6)1-2-4(7)8/h1-4,8-15,21H,5-7,16-20,22H2;1-2H,(H,5,6)(H,7,8)/b;2-1+

SMILES Code: FC1=CC=C(N2C=C(CCCCN3CCC4(CC3)OCC5=C4C=CC=C5)C6=C2C=CC=C6)C=C1.O=C(O)/C=C/C(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Biological target: Siramesine is a sigma receptor agonist, selective for the σ2 subtype In animal studies, siramesine produced anxiolytic and antidepressant effects. Siramesine has been shown to produce an enhanced antidepressant effect when co-administered with NMDA antagonists. It has also been used to study the σ2 activity of cocaine, and has been shown to produce anticancer properties both in vitro and in vivo.
In vitro activity: Cell death in siramesine-treated cells is mitochondria-dependent and occurs independently of lysosomal membrane permeabilization. Siramesine induces rapid cell death in a number of cell lines. In HaCaT cells, cell death was accompanied by caspase activation, rapid loss of mitochondrial membrane potential (MMP), cytochrome c release, cardiolipin peroxidation and typical apoptotic morphology, whereas in U-87MG cells most apoptotic hallmarks were not notable, although MMP was rapidly lost. Reference: Cell Death Dis. 2013 Oct 3;4(10):e818. https://pubmed.ncbi.nlm.nih.gov/24091661/
In vivo activity: Siramesine holds promise as a treatment for cutaneous mastocytoses and inflammatory skin diseases aggravated by dermal mast cells. Siramesine significantly reduced the total number of mast cells in both lesional and uninvolved psoriatic skin biopsies without affecting the gross morphology of the tissue. Siramesine reduced the density of IL-6- and IL-17-positive mast cells, and showed antiproliferative effects on epidermal keratinocytes with no apparent cytotoxic effect on keratinocytes or dermal fibroblasts. Reference: Br J Dermatol. 2017 Jul;177(1):179-187. https://pubmed.ncbi.nlm.nih.gov/28117878/

Preparing Stock Solutions

The following data is based on the product molecular weight 570.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Garcia EA, Bhatti I, Henson ES, Gibson SB. Prostate Cancer Cells Are Sensitive to Lysosomotropic Agent Siramesine through Generation Reactive Oxygen Species and in Combination with Tyrosine Kinase Inhibitors. Cancers (Basel). 2022 Nov 8;14(22):5478. doi: 10.3390/cancers14225478. PMID: 36428570; PMCID: PMC9688505. 2. Česen MH, Repnik U, Turk V, Turk B. Siramesine triggers cell death through destabilisation of mitochondria, but not lysosomes. Cell Death Dis. 2013 Oct 3;4(10):e818. doi: 10.1038/cddis.2013.361. PMID: 24091661; PMCID: PMC3824671. 3. Klawonn AM, Nilsson A, Rådberg CF, Lindström SH, Ericson M, Granseth B, Engblom D, Fritz M. The Sigma-2 Receptor Selective Agonist Siramesine (Lu 28-179) Decreases Cocaine-Reinforced Pavlovian Learning and Alters Glutamatergic and Dopaminergic Input to the Striatum. Front Pharmacol. 2017 Oct 10;8:714. doi: 10.3389/fphar.2017.00714. PMID: 29066971; PMCID: PMC5641388. 4. Hagforsen E, Lampinen M, Paivandy A, Weström S, Velin H, Öberg S, Pejler G, Rollman O. Siramesine causes preferential apoptosis of mast cells in skin biopsies from psoriatic lesions. Br J Dermatol. 2017 Jul;177(1):179-187. doi: 10.1111/bjd.15336. Epub 2017 May 15. PMID: 28117878.
In vitro protocol: 1. Garcia EA, Bhatti I, Henson ES, Gibson SB. Prostate Cancer Cells Are Sensitive to Lysosomotropic Agent Siramesine through Generation Reactive Oxygen Species and in Combination with Tyrosine Kinase Inhibitors. Cancers (Basel). 2022 Nov 8;14(22):5478. doi: 10.3390/cancers14225478. PMID: 36428570; PMCID: PMC9688505. 2. Česen MH, Repnik U, Turk V, Turk B. Siramesine triggers cell death through destabilisation of mitochondria, but not lysosomes. Cell Death Dis. 2013 Oct 3;4(10):e818. doi: 10.1038/cddis.2013.361. PMID: 24091661; PMCID: PMC3824671.
In vivo protocol: 1. Klawonn AM, Nilsson A, Rådberg CF, Lindström SH, Ericson M, Granseth B, Engblom D, Fritz M. The Sigma-2 Receptor Selective Agonist Siramesine (Lu 28-179) Decreases Cocaine-Reinforced Pavlovian Learning and Alters Glutamatergic and Dopaminergic Input to the Striatum. Front Pharmacol. 2017 Oct 10;8:714. doi: 10.3389/fphar.2017.00714. PMID: 29066971; PMCID: PMC5641388. 2. Hagforsen E, Lampinen M, Paivandy A, Weström S, Velin H, Öberg S, Pejler G, Rollman O. Siramesine causes preferential apoptosis of mast cells in skin biopsies from psoriatic lesions. Br J Dermatol. 2017 Jul;177(1):179-187. doi: 10.1111/bjd.15336. Epub 2017 May 15. PMID: 28117878.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Česen MH, Repnik U, Turk V, Turk B. Siramesine triggers cell death through destabilisation of mitochondria, but not lysosomes. Cell Death Dis. 2013 Oct 3;4:e818. doi: 10.1038/cddis.2013.361. PubMed PMID: 24091661; PubMed Central PMCID: PMC3824671.

2: Spirkoski J, Melo FR, Grujic M, Calounova G, Lundequist A, Wernersson S, Pejler G. Mast cell apoptosis induced by siramesine, a sigma-2 receptor agonist. Biochem Pharmacol. 2012 Dec 15;84(12):1671-80. doi: 10.1016/j.bcp.2012.09.028. PubMed PMID: 23058984.

3: Ma S, Henson ES, Chen Y, Gibson SB. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis. 2016 Jul 21;7:e2307. doi: 10.1038/cddis.2016.208. PubMed PMID: 27441659; PubMed Central PMCID: PMC4973350.

4: Ostenfeld MS, Høyer-Hansen M, Bastholm L, Fehrenbacher N, Olsen OD, Groth-Pedersen L, Puustinen P, Kirkegaard-Sørensen T, Nylandsted J, Farkas T, Jäättelä M. Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation. Autophagy. 2008 May;4(4):487-99. PubMed PMID: 18305408.

5: Jonhede S, Petersen A, Zetterberg M, Karlsson JO. Acute effects of the sigma-2 receptor agonist siramesine on lysosomal and extra-lysosomal proteolytic systems in lens epithelial cells. Mol Vis. 2010 May 8;16:819-27. PubMed PMID: 20461150; PubMed Central PMCID: PMC2866574.

6: Hagforsen E, Lampinen M, Paivandy A, Weström S, Velin H, Öberg S, Pejler G, Rollman O. Siramesine causes preferential apoptosis of mast cells in skin biopsies from psoriatic lesions. Br J Dermatol. 2017 Jan 24. doi: 10.1111/bjd.15336. [Epub ahead of print] PubMed PMID: 28117878.

7: Ostenfeld MS, Fehrenbacher N, Høyer-Hansen M, Thomsen C, Farkas T, Jäättelä M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res. 2005 Oct 1;65(19):8975-83. PubMed PMID: 16204071.

8: Zimmermann A, Tian F, Lopez de Diego H, Ringkjøbing Elema M, Rantanen J, Müllertz A, Hovgaard L. Influence of the solid form of siramesine hydrochloride on its behavior in aqueous environments. Pharm Res. 2009 Apr;26(4):846-54. doi: 10.1007/s11095-008-9783-0. PubMed PMID: 19005740.

9: Parry MJ, Alakoskela JM, Khandelia H, Kumar SA, Jäättelä M, Mahalka AK, Kinnunen PK. High-affinity small molecule-phospholipid complex formation: binding of siramesine to phosphatidic acid. J Am Chem Soc. 2008 Oct 1;130(39):12953-60. doi: 10.1021/ja800516w. PubMed PMID: 18767848.

10: Zimmermann A, Tian F, de Diego HL, Frydenvang K, Rantanen J, Elema MR, Hovgaard L. Structural characterisation and dehydration behaviour of siramesine hydrochloride. J Pharm Sci. 2009 Oct;98(10):3596-607. doi: 10.1002/jps.21679. PubMed PMID: 19156865.

11: Groth-Pedersen L, Ostenfeld MS, Høyer-Hansen M, Nylandsted J, Jäättelä M. Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Res. 2007 Mar 1;67(5):2217-25. PubMed PMID: 17332352.

12: Søby KK, Mikkelsen JD, Meier E, Thomsen C. Lu 28-179 labels a sigma(2)-site in rat and human brain. Neuropharmacology. 2002 Jul;43(1):95-100. PubMed PMID: 12213263.

13: Zimmermann A, Millqvist-Fureby A, Elema MR, Hansen T, Müllertz A, Hovgaard L. Adsorption of pharmaceutical excipients onto microcrystals of siramesine hydrochloride: effects on physicochemical properties. Eur J Pharm Biopharm. 2009 Jan;71(1):109-16. doi: 10.1016/j.ejpb.2008.06.014. PubMed PMID: 18619536.

14: Nielsen AB, Buur A, Larsen C. Bioreversible quaternary N-acyloxymethyl derivatives of the poorly soluble tertiary amine Lu 28-179--synthesis, pharmaceutical chemical characterization and bioavailability studies in dogs. Eur J Pharm Sci. 2005 Dec;26(5):421-8. PubMed PMID: 16150581.

15: Sánchez C, Papp M. The selective sigma2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. Behav Pharmacol. 2000 Apr;11(2):117-24. PubMed PMID: 10877116.

16: Heading C. Siramesine H Lundbeck. Curr Opin Investig Drugs. 2001 Feb;2(2):266-70. Review. PubMed PMID: 11816842.

17: Sánchez C, Arnt J, Costall B, Kelly ME, Meier E, Naylor RJ, Perregaard J. The selective sigma2-ligand Lu 28-179 has potent anxiolytic-like effects in rodents. J Pharmacol Exp Ther. 1997 Dec;283(3):1323-32. Erratum in: J Pharmacol Exp Ther 1998 May;285(2):929. PubMed PMID: 9400007.

18: Hagforsen E, Paivandy A, Lampinen M, Weström S, Calounova G, Melo FR, Rollman O, Pejler G. Ablation of human skin mast cells in situ by lysosomotropic agents. Exp Dermatol. 2015 Jul;24(7):516-21. doi: 10.1111/exd.12699. PubMed PMID: 25808581.

19: Petersen NH, Olsen OD, Groth-Pedersen L, Ellegaard AM, Bilgin M, Redmer S, Ostenfeld MS, Ulanet D, Dovmark TH, Lønborg A, Vindeløv SD, Hanahan D, Arenz C, Ejsing CS, Kirkegaard T, Rohde M, Nylandsted J, Jäättelä M. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell. 2013 Sep 9;24(3):379-93. doi: 10.1016/j.ccr.2013.08.003. PubMed PMID: 24029234.

20: Skuza G, Rogóz Z. The synergistic effect of selective sigma receptor agonists and uncompetitive NMDA receptor antagonists in the forced swim test in rats. J Physiol Pharmacol. 2006 Jun;57(2):217-29. PubMed PMID: 16845227.